Global Intravenous Immunoglobulin Market Size & Outlook
Global intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Global intravenous immunoglobulin market highlights
- The global intravenous immunoglobulin market generated a revenue of USD 13,857.6 million in 2024 and is expected to reach USD 21,053.5 million by 2030.
- The market is expected to grow at a CAGR (2025 - 2030) of 7.2% by 2030.
- In terms of segment, immunodeficiency diseases accounted for a revenue of USD 2,906.9 million in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Global data book summary
| Market revenue in 2024 | USD 13,857.6 million |
| Market revenue in 2030 | USD 21,053.5 million |
| Growth rate | 7.2% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
Other key industry trends
- In terms of revenue, the North America accounted for 46.1% of the global intravenous immunoglobulin market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, China is the fastest growing regional market and is projected to reach USD 1,078.8 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 20.98% in 2024. Horizon Databook has segmented the Global intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
Market Dynamics
Primary Immune Deficiency (PID) diseases represent a group of disorders characterized by a complete lapse in the immune system. There are over 430 different PIDs such as specific antibody deficiency, X-ined hypogammaglobulinemia, Wiscott -Aldrich syndrome, Di George syndrome, and Ataxia-telangectasia, among others.
The most common uses of intravenous immunoglobulin are seen the treatment of Gullian Barre syndrome, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, dermatomyositis and inflammatory myopathies, Myasthenia gravis, Lambert & Eaton syndrome, and stiff person syndrome, among others. As per a study published by U.S.
National Library of Medicine and National Institute of Health, approximately 6 million patients are typically affected by PID worldwide with almost 90% of these cases remaining undiagnosed. Individuals suffering from PIDs are therefore vulnerable to other infections and other severe autoimmunity, malignancy, auto inflammation, and allergies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Taibang Biological Group | View profile | 1001-5000 | Beijing, Beijing, China, Asia | http://en.chinabiologic.com/ |
| LFB (Laboratoire Français du Fractionnement et des Biotechnologies) | View profile | 1001-5000 | Courceboeufs, Pays de la Loire, France, Europe | http://www.groupe-lfb.com |
| Kedrion Biopharma | View profile | 1001-5000 | Fort Lee, New Jersey, United States, North America | https://www.kedrion.com/ |
| Octapharma AG | View profile | 10001+ | Lachen, Schwyz, Switzerland, Europe | http://www.octapharma.com/en.html |
| Biotest AG ADR | View profile | 2426 | Landsteinerstrasse 5, Dreieich, Germany, 63303 | https://www.biotest.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| Baxter International Inc | View profile | 60000 | One Baxter Parkway, Deerfield, IL, United States, 60015 | https://www.baxter.com |
Global intravenous immunoglobulin market size, by regions, 2018-2030 (US$M)
Top 10 countries: Intravenous immunoglobulin market size, 2024 (US$M)
Global intravenous immunoglobulin market share, by application, 2024 & 2030 (%, US$M)
Intravenous immunoglobulin market: Opportunity assessment by country
Global intravenous immunoglobulin market, by region, 2024 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
